Floatz logo

Etarfolatide

Testicular Cancer

Endocyteprotein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

11 Active assets in the Testicular Cancer cohort.

Asset / SponsorPhaseRating
TESTOSTERONE UNDECYLATE
University Medical Center Groningen
Phase 2/3BB
FLUOROURACILUM
National Cancer Institute (NCI)
Phase 2B
Flavopiridol
National Cancer Institute (NCI)
Phase 2B
Eloxatin
National Cancer Institute (NCI)
Phase 2B
Durvalumab
Ludwig Institute for Cancer Research
Phase 1/2CCC

View all 20 →

Same molecule, other indications

Etarfolatide is also rated in:

ovarian cancerDormant
B
Indicative ·
58 / 100
View asset →
lung adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →
ovarian carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →